Tierra Biosciences’ Post

De novo molecular generation and activity optimization of proteins is within reach with the Tierra Flywheel. Please use the #BIO2024 partnering link below to meet with our CEO Michael Nemzek in San Diego to learn more. https://lnkd.in/gHWNqxv6 #pharma #proteins #therapeutics #artificialintelligence #largelanguagemodels

The March issue of TPharm is now live! Read about the bacteria Clostridium difficile, the health problems it causes and the historical path to effective treatment options and therapeutics. Read the issue here: https://bit.ly/3TEcTSC #pharmacology

Weekly insulin shot 💉 already approved in Canada Switzerland and Europe. #update FDA votes against approval says more trials are needed to examine hypoglycemia risk in T1D. 2,259 views Streamed live on May 24, 2024 At this meeting, the committee will discuss the safety and efficacy of biologics license application (BLA) 761326 for NNC0148-0287 injection (insulin icodec), a long-acting insulin analog product, submitted by Novo Nordisk. The proposed indication is to improve glycemic control in adults with diabetes mellitus.

Elevate the level of care in your SNF with PGX Testing: Psychotropic and Antipsychotic medications have been linked to falls for nursing home residents with certain conditions. Utilizing PGX Testing in a SNF/ALF can help check efficacy, toxicity and compatibility of the drug for the resident- which can ultimately prevent falls. Email me at Shimi@medmor.org #genome #genetics #pharmaceutical #medication #safety

PRODRUG A prodrug is a pharmacologically inactive compound that undergoes metabolic or chemical transformation within the body to release the active drug. The objectives of using prodrugs include: Enhanced bioavailability: Prodrugs can improve the absorption and distribution of the active drug, leading to increased bioavailability and therapeutic efficacy. Improved drug delivery: Prodrugs can be designed to target specific tissues or cells, allowing for targeted delivery and reduced systemic side effects. Enhanced stability: Prodrugs can protect the active drug from degradation or metabolism, increasing its stability and prolonging its half-life in the body. Reduced toxicity: Prodrugs can be engineered to minimize the toxicity of the active drug, either by targeting specific metabolic pathways or by reducing off-target effects. Improved patient compliance: Prodrugs can be formulated into more convenient dosage forms (e.g., oral tablets, injectables) or administered less frequently, improving patient adherence to treatment regimens. Overall, prodrugs offer a versatile approach to optimizing the pharmacokinetic and pharmacodynamic properties of drugs, ultimately leading to improved therapeutic outcomes. some common prodrugs are: Aspirin (acetylsalicylic acid) Lisdexamfetamine (Vyvanse) Enalapril (Vasotec) Levodopa (L-DOPA) Prednisone (prednisolone) Omeprazole (omeprazole magnesium) Cyclophosphamide (ifosfamide) Dipivefrin (epinephrine) Codeine (morphine) Captopril (captopril disulfide) Albuterol (levosalbutamol) Penciclovir (famciclovir) Sulindac (sulindac sulfide) Isoniazid (isoniazid hydrazide) #pharma #pharmacist #pharmceutics #Medicine

Cholesterol-lowering #statins already improve the lives of millions of people worldwide – and they could soon be helping fight gum disease, too.💡 > Researchers at the Medical University of South Carolina have built upon previous studies suggesting that people who take statins tend to show fewer signs of gum infection, or periodontitis. > They discovered that the common statin drug simvastatin suppressed the inflammatory response generated by macrophages – a type of white blood cell key to the body’s immune system. > If further studies using statins on animals with gum disease prove successful, the treatment could potentially become a safe new way to combat periodontitis in humans. 🔬 LGC Standards supports statins research and analysis with 100+ TRC #ResearchChemicals and 60+ high quality #pharmaceutical #ReferenceMaterials from Mikromol: https://okt.to/OysE2B #ScienceForASaferWorld

Drug dose adjustments in Renal Failure in small animals: Why? 1) RF dec filtration of renally eliminated drugs and active metabolites 2) Dec tubular secretion of (digoxin, cimetidine,quinidine, TMS) 3) Dec binding of some drugs to albumin (furosemide, sulfa, aspirin) What drug doses to decrease? 1) Penicillins 2) Cephalosporins 3) Fluroquinolones extend dosing interval (48 hr instead of 24hr)of enro or chose less renotoxic like marbofloxacin) 4) Aminoglycosides (rehydrate first, use with fluids, use less nephrotoxic i.e amikacin), don't use aminoglycosides in obstruction,limit therapy to 5 days or less if possible. HOW TO MONITOR? Check daily fresh urine sediment for granular casts 5) use doxy not tetra(can inc BUN, breakdown products are renotoxic) 6) Sulfonamides, chloramphenicol, Digioxin, Furosemide, Metoclopramide, Atenolol, 7) use benzapril instead of enalpril in renal failure(all are renal toxic, monitor by BUN, Cr) 8) NSAIDs Use alternatives in azotemic patients like tramadol, buprenophine, chondroitin, SAMe Ref: plumbs, https://lnkd.in/d_JamEqT

Opicapone, a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-O-methyltransferase (COMT). This enzyme plays a crucial role in the breakdown of various catecholamines, including dopamine. Many patients with Parkinson's disease treated with levodopa and a dopa decarboxylase (DDC) inhibitor (like carbidopa) experience motor complications over time. To manage these symptoms, options include dopamine agonists, monoamine oxidase B inhibitors (such as selegiline and rasagiline), COMT inhibitors, amantadine, or modified-release formulations of levodopa. Opicapone stands out as an effective adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease experiencing end-of-dose motor fluctuations. Approved by the European Commission in June 2016 and the FDA in April 2020, Opicapone (marketed as Ongentys) is available as once-daily oral capsules. Its long duration of action exceeds 24 hours, offering the convenience of once-daily administration. Additionally, it demonstrates the lowest risk for cytotoxicity among COMT inhibitors. Why Royal Pharma ? 1. We are Completely backward integrated offering all the intermediates of this molecule ( End-to-end soln provider) 2. With our FDA-Approved Site (For advanced intermediates ) in compliance with WHO-GMP, We ensure to match quality as per industry standards & strong regulatory support. 3. One of the early movers in the market – producing all the intermediates in-house & ensuring no reliability on imports for KSMs Tech Pack is available – For more details contact us at: sales@royalpharma.in . . . #RoyalPharma #RoyalPharmaIndia #Opicapone #ParkinsonsTreatment #ISOcertified #QualityControl #PharmaSolutions

Cholesterol-lowering #statins already improve the lives of millions of people worldwide – and they could soon be helping fight gum disease, too.💡 > Researchers at the Medical University of South Carolina have built upon previous studies suggesting that people who take statins tend to show fewer signs of gum infection, or periodontitis. > They discovered that the common statin drug simvastatin suppressed the inflammatory response generated by macrophages – a type of white blood cell key to the body’s immune system. > If further studies using statins on animals with gum disease prove successful, the treatment could potentially become a safe new way to combat periodontitis in humans. 🔬 LGC Standards supports statins research and analysis with 100+ TRC #ResearchChemicals and 60+ high quality #pharmaceutical #ReferenceMaterials from Mikromol: https://okt.to/47Wgyu #ScienceForASaferWorld

According to Precision Business Insights the global #coagulation #factor #deficiency market size was valued at USD 14.2 billion in 2022, at a CAGR of 6.7% during the forecast period 2023-29. 𝐁𝐲 𝐃𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐓𝐲𝐩𝐞: The market is segmented into #hemophilia A, #hemophilia B, #von #willebrand #disease, #Factor XI #deficiency, #factor XIII Deficiency, and #others 𝐁𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞: The market is segmented into #plasma #derived #coagulation #factor #concentrates, #recombinant #coagulation #factor #concentrates, #biologics, #desmopressin, and #others 𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫𝐬: The market is segmented into #hospitals, #clinics, #homecare, #others Biogen, Grifols, Pfizer, Octapharma, Baxter International Inc., Bayer, CSL Behring B.V., Novo Nordisk, Greencross Vets, Kedrion Biopharma, BPL Medical Technologies Pvt Ltd, Hualan Biological Engineering Inc., #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand